In contrast to this relatively small sample size and specific features in this cohort, our present study is the first to examine the prognostic impact of the pretreatment ALI in a relatively large cohort of PC patients across all tumor stages including chemotherapy and with inclusion of the CRP levels as another systemic inflammation response marker. The gene discussed is CRP; the disease is pachyonychia congenita.